Pfizer's AML med Mylotarg wins FDA approval for the second time

1st September 2017 Uncategorised 0

After being on the market for 10 years and withdrawn for 7 years, Pfizer’s Mylotarg is set to make its return. The targeted acute myeloid leukemia drug on Friday won the FDA’s backing, again, marking the latest twist in its decades-long saga.

More: Pfizer's AML med Mylotarg wins FDA approval for the second time
Source: fierce